GET DAILY SIGNALSProMIS Neurosciences (PMN) Narrows Third-Quarter Loss to $8.2 Million
Key Takeaways
- ProMIS Neurosciences reported a third quarter 2026 net loss of $8.2 million, or $(0.89) per share, narrowing from $11.6 million, or $(5.93) per share, in the same period a year earlier.
- The reported net loss per share of $(0.89) came in ahead of the consensus estimate of roughly $(1.26), a modest beat on the bottom line.
- Cash stood at $44.1 million as of September 30, 2026, which management expects to fund operations through 2027 — beyond the anticipated PMN310 data readout.
- Research and development (R&D) expenses fell 32% year over year to $6.7 million as the PMN310 Phase 1b trial moved toward completion of patient visits.
- Management reaffirmed its first quarter 2027 topline data timing for the PRECISE-AD study of PMN310 in Alzheimer's disease.
- For additional context on PMN, explore the Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover Trending AI Robots to explore AI-driven trading tools and signals.
Earnings Context and Why It Matters
ProMIS Neurosciences is a clinical-stage biotechnology company focused on antibody therapies and vaccines aimed at toxic misfolded proteins tied to neurodegenerative conditions. Its lead asset, PMN310, is advancing in the PRECISE-AD Phase 1b trial for Alzheimer’s disease. With no product revenue yet, attention centers on cash runway, spending control, and clinical milestones rather than sales figures. This update is relevant because it indicates whether PMN can reach the key PMN310 readout without needing fresh capital, and whether spending patterns point to a disciplined approach for later-stage work. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
In the third quarter ended September 30, 2026, ProMIS Neurosciences posted a net loss of $8.2 million, or $(0.89) per basic and diluted share, versus a net loss of $11.6 million, or $(5.93) per share, a year earlier. The figure came in better than the consensus estimate of about $(1.26) per share.
Research and development expenses totaled $6.7 million, a 32% drop from $9.8 million in the prior-year quarter. The decline stemmed mainly from a $3.6 million cut in direct PMN310 costs as the PRECISE-AD trial approached the end of patient visits, partly offset by higher activity in the ALS program and platform efforts. General and administrative expenses were $1.9 million, essentially unchanged from $2.0 million. Other income increased to $0.5 million from $0.2 million due to higher interest income.
For the first nine months of 2026, the net loss was $28.1 million, or $(3.39) per share, compared with $29.0 million, or $(19.58) per share, in the same stretch of 2025. Cash and equivalents reached $44.1 million at quarter-end, up from $6.1 million at the end of 2025, thanks to $70.1 million in net proceeds from a January 2026 private placement.
Market Reaction and Investor Sentiment
Shares of PMN had faced pressure before the release, sitting well below their 52-week high amid clinical-stage uncertainties and a steep decline over the past year. After the announcement, the stock moved modestly higher in after-hours trading as the narrower loss and confirmed data timeline offered some reassurance. Sentiment stays closely linked to the PMN310 program, with price targets spanning a broad range depending on whether Phase 1b results support progression to a registration-enabling study. The main near-term risk remains the binary nature of the clinical data, which can trigger sharp moves in either direction.
Forward Outlook and Key Factors to Monitor
The primary catalyst remains the PRECISE-AD topline data, which management continues to target for the first quarter of 2027. Investors will focus on whether the results support advancing PMN310 into a later-stage study, a call that will also factor in final data and any input from the FDA.
Financially, the $44.1 million cash balance is projected to cover operations through 2027, easing immediate dilution concerns. That said, spending could increase if ProMIS moves forward with additional programs such as ALS or platform work, or begins preparations for Phase 3 trials.
Updates on subcutaneous dosing and Phase 3 trial design, which management expects to shape based on the upcoming readout, will also draw attention. Broader market views on amyloid-targeting Alzheimer’s therapies and competitive data from peers could further color how results for PMN are interpreted.
Using Tickeron’s AI Screener for Sector Comparisons
In my own review of clinical-stage names like PMN, I often rely on Tickeron’s AI Screener to quickly surface comparable biotech opportunities. The tool lets me apply filters for fundamentals, technical patterns, and sector trends, which helps put individual company updates into broader context without spending hours on manual checks. It has become a regular part of how I evaluate names in this space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PMN's RSI Indicator ascends from oversold territory
The RSI Indicator for PMN moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 154 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMN as a result. In 98 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.755) is normal, around the industry mean (3.498). P/E Ratio (-0.330) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement